DZ3361A1 - Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda - Google Patents

Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda

Info

Publication number
DZ3361A1
DZ3361A1 DZ013361A DZ013361A DZ3361A1 DZ 3361 A1 DZ3361 A1 DZ 3361A1 DZ 013361 A DZ013361 A DZ 013361A DZ 013361 A DZ013361 A DZ 013361A DZ 3361 A1 DZ3361 A1 DZ 3361A1
Authority
DZ
Algeria
Prior art keywords
cyclohexylamines
bicyclic
antagonists
nmda receptors
nmda
Prior art date
Application number
DZ013361A
Other languages
English (en)
Inventor
Brian Alan Sherer
Ian Leslie Scott
Sham Shridhar Nikam
Lawrence David Wise
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3361A1 publication Critical patent/DZ3361A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ013361A 2000-05-31 2001-05-08 Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda DZ3361A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824100P 2000-05-31 2000-05-31
PCT/US2001/014763 WO2001092239A1 (fr) 2000-05-31 2001-05-08 Cyclohexylamines bicycliques et leur utilisation comme antagonistes du recepteur de nmda (n-methyl-d-aspartate)

Publications (1)

Publication Number Publication Date
DZ3361A1 true DZ3361A1 (fr) 2001-12-06

Family

ID=22773822

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013361A DZ3361A1 (fr) 2000-05-31 2001-05-08 Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda

Country Status (28)

Country Link
US (1) US6794402B2 (fr)
EP (1) EP1286975B1 (fr)
JP (1) JP2003535083A (fr)
KR (1) KR20030007797A (fr)
CN (1) CN1438996A (fr)
AP (1) AP2002002697A0 (fr)
AT (1) ATE302763T1 (fr)
AU (1) AU2001259618A1 (fr)
BG (1) BG107375A (fr)
BR (1) BR0111301A (fr)
CA (1) CA2409006A1 (fr)
DE (1) DE60112924T2 (fr)
DZ (1) DZ3361A1 (fr)
EA (1) EA200201158A1 (fr)
EE (1) EE200200667A (fr)
ES (1) ES2245985T3 (fr)
HR (1) HRP20021018A2 (fr)
HU (1) HUP0302323A2 (fr)
IL (1) IL153170A0 (fr)
IS (1) IS6625A (fr)
MA (1) MA26907A1 (fr)
MX (1) MXPA02011926A (fr)
NO (1) NO20025762L (fr)
OA (1) OA12275A (fr)
PL (1) PL359260A1 (fr)
SK (1) SK16632002A3 (fr)
WO (1) WO2001092239A1 (fr)
ZA (1) ZA200209325B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002749A (es) * 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
GB0116594D0 (en) * 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds
DE10210779A1 (de) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
EP1511736A4 (fr) * 2002-06-07 2006-06-07 Cortical Pty Ltd Molecules therapeutiques et procedes - 1
ATE437639T1 (de) 2002-12-20 2009-08-15 Cancer Rec Tech Ltd 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)- cyclohexa-2,5-dienone verbindungen und ihre analoge als therapeutische wirkstoffe
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
JP5270943B2 (ja) * 2008-03-28 2013-08-21 大阪瓦斯株式会社 フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
AR080056A1 (es) * 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2013111798A1 (fr) 2012-01-27 2013-08-01 国立大学法人 富山大学 Inhibiteur de la sérine racémase
CN105152966A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种叠氮化合物的制备方法
CN105001118A (zh) * 2015-07-20 2015-10-28 湖南华腾制药有限公司 一种含碘叠氮化合物的制备方法
CN105061254A (zh) * 2015-07-20 2015-11-18 湖南华腾制药有限公司 一种含溴叠氮化合物的合成方法
CN105153020A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种芳香叠氮化合物的制备方法
WO2018033525A1 (fr) * 2016-08-16 2018-02-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonistes ou agonistes partiels du site d'histamine du récepteur nmda pour l'utilisation dans le traitement de maladies du système nerveux central
CN107043335A (zh) * 2017-05-31 2017-08-15 湖南华腾制药有限公司 一种2‑氟苯基叠氮化合物的制备方法
WO2019043217A1 (fr) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
WO2025232878A1 (fr) * 2024-05-09 2025-11-13 苏州旺山旺水生物医药股份有限公司 Composé amine contenant un phényle substitué, son procédé de préparation et son utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438055A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K Ring- und N-substituierte N-Benzyl-cycloalkylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (fr) 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Utilisation de dérivés d'aryl-cyclohexylamine dans la fabrication d'agents bloquants du récepteur NMDA

Also Published As

Publication number Publication date
OA12275A (en) 2003-12-11
BR0111301A (pt) 2003-06-10
ZA200209325B (en) 2004-02-16
DE60112924T2 (de) 2006-03-16
HUP0302323A2 (hu) 2003-10-28
MXPA02011926A (es) 2003-04-22
IS6625A (is) 2002-11-18
AP2002002697A0 (en) 2002-12-31
CA2409006A1 (fr) 2001-12-06
WO2001092239A1 (fr) 2001-12-06
ATE302763T1 (de) 2005-09-15
DE60112924D1 (de) 2005-09-29
US6794402B2 (en) 2004-09-21
EP1286975A1 (fr) 2003-03-05
NO20025762L (no) 2003-01-09
EE200200667A (et) 2004-06-15
MA26907A1 (fr) 2004-12-20
HRP20021018A2 (en) 2004-02-29
SK16632002A3 (sk) 2003-08-05
CN1438996A (zh) 2003-08-27
BG107375A (bg) 2003-09-30
JP2003535083A (ja) 2003-11-25
US20030236252A1 (en) 2003-12-25
KR20030007797A (ko) 2003-01-23
AU2001259618A1 (en) 2001-12-11
PL359260A1 (en) 2004-08-23
NO20025762D0 (no) 2002-11-29
IL153170A0 (en) 2003-06-24
ES2245985T3 (es) 2006-02-01
EA200201158A1 (ru) 2003-04-24
EP1286975B1 (fr) 2005-08-24

Similar Documents

Publication Publication Date Title
DZ3361A1 (fr) Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda
FR14C0017I2 (fr) Nouveaux sulfamides et leur utilisation comme antagonistes du recepteur de l'endotheline
MA26773A1 (fr) Derives de 3-phenylpyridine et leur utilisation comme recepteurs antagonistes nk-1
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
PT968194E (pt) Atropisomeros de 3-aril-4(3h)-quinazolinonas e sua utilizacao como antagonistas dos receptores ampa
PL363011A1 (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
FR15C0049I2 (fr) Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
AU2002213409A1 (en) Galphaqproetin variants and their use in the analysis and discovery of agonists and antagonists of chemosensory receptors
PL365183A1 (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor
SI1170288T1 (en) Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
IL158701A0 (en) Novel use of nk3 receptor antagonist
PT1036072E (pt) Antagonistas de receptores de trombina
IL152701A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
IL145334A0 (en) The use of certain affinity nmda antagonists as antidepressants
AU2003260072A8 (en) Antagonists of chemokine receptors
ATE374183T1 (de) Nk1-antagonisten
EP1734966A4 (fr) Utilisation de derives de piperazinylpiperidine comme antagonistes de recepteurs de chimiokines
EP1171152A4 (fr) ANTAGONISTES PEPTIDIQUES vMIP-II DE CXCR4
GB0011817D0 (en) Antagonists of integrin receptors
ID30484A (id) Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin
DK1073431T3 (da) Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom
AU2002302735A1 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists